Antidote.me
Antidote.me is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Antidote.me.
Antidote.me is a company.
Key people at Antidote.me.
Antidote.me (Antidote Technologies) is a digital health company that builds Antidote Match™, a clinical trial matching platform connecting patients to relevant trials by structuring global trial data into a machine-readable format. Patients answer simple questions to find matching studies, while researchers gain precision recruitment tools for faster enrollment.[1][3][8] It serves patients seeking treatment options, clinical trial sponsors like Pfizer and Eli Lilly, health systems, nonprofits, and over 250 patient communities reaching 15 million patients monthly, solving the core problem where 80-85% of trials delay or close due to participant shortages.[1][2][3]
The platform drives growth through partnerships with pharma giants, health tech firms like SEQSTER and PatientPoint, and nonprofits such as Breakthrough T1D and Beyond Type 1, emphasizing diversity, equity, and inclusion (DEI) in trials.[2][3][5][6] Antidote provides free search tech to advocacy groups while offering customized solutions to sponsors, reducing site burden and accelerating medical breakthroughs.[5]
Founded in 2010 in Noblesville, Indiana (with operations in the US and UK), Antidote launched as TrialReach before rebranding.[1][3] It emerged from the recognition that 85% of patients are unaware of trials and struggle to qualify, causing 80% of studies to delay—slowing medical progress.[1][3][8] Key leaders include CEO Laurent Schockmel, Co-CEO Samantha Veeck, and a team focused on high-tech, high-touch recruitment.[3][5]
Pivotal early traction came from pharma collaborations in 2015, where Pfizer, Eli Lilly, and Novartis selected Antidote to convert trial data into machine-readable formats, forming a consortium.[2] Over 12+ years, it built 300+ partnerships with nonprofits, bloggers, and tech firms, evolving from a search tool to a global recruiter powering trial awareness for millions.[2][3][5]
Antidote rides the digital health and patient-centric research wave, addressing recruitment bottlenecks amid rising trial complexity and DEI mandates from regulators like the FDA.[4][6] Timing aligns with post-pandemic telehealth growth and AI data structuring, where 80% trial delays cost billions annually—Antidote's platform counters this by democratizing access.[1][3][8] Market forces like pharma's push for faster drug development (e.g., oncology, rare diseases) and nonprofit demands for inclusive trials favor its model.[2][6]
It influences the ecosystem by powering searches for millions, partnering with health systems and tech (e.g., PatientPoint integration at doctor visits), and enabling breakthroughs—e.g., Spanish tools for underrepresented diabetes patients—shifting trials from siloed to collaborative, global efforts.[3][5][6]
Antidote is poised to expand its recruiter dominance through deeper AI integrations, more DEI-focused tools, and alliances like SEQSTER for real-time data, targeting even faster enrollments amid growing trial volumes.[5] Trends like personalized medicine, regulatory DEI requirements, and point-of-care tech will propel it, potentially scaling to billions in impact as trials digitize fully. Its influence may evolve into a standard infrastructure layer for research, bridging patients and cures more inclusively—reinforcing its core mission to end the participation crisis that stalls 80% of studies.[1][3][8]
Key people at Antidote.me.
